Effects of Rituximab, Bortezomib, and Bendamustine on the Survival in Medicare Beneficiaries with Mantle Cell Lymphoma

被引：0

作者：

Fu, Shuangshuang ^{[1
,3
]}

Wang, Michael ^{[2
]}

Zhao, Hui ^{[3
]}

Li, Ruosha ^{[4
]}

Lairson, David ^{[5
]}

Giordano, Sharon ^{[3
]}

Zhao, Bo ^{[4
]}

Du, Xianglin ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr Houston, Dept Epidemiol Human Genet & Environm Sci, Sch Publ Hlth, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Div Canc Prevent & Populat Sci, Houston, TX 77030 USA

[4] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Sch Publ Hlth, Houston, TX 77030 USA

[5] Univ Texas Hlth Sci Ctr Houston, Dept Management Policy & Community Hlth, Sch Publ Hlth, Houston, TX 77030 USA

来源：

关键词：

mantle cell lymphoma; effectiveness; rituximab; bortezomib; bendamustine;

D O I：

10.1016/j.clml.2018.07.198

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NHL-072

引用

页码：S273 / S274

页数：2